8 unknown, 3 not yet recruiting, 1 active not recruiting, 1 completed. 6 Phase 2, 4 Phase 3, 3 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Not yet recruiting 3, Unknown 3 |
| Phase 3 | 4 | Unknown 3, Active not recruiting 1 |
| Phase 1 | 3 | Not yet recruiting 2, Completed 1 |
| Not applicable | 2 | Unknown 2 |
Follow Aclarubicin: new trials by email Literature Review of Aclarubicin trials Research Report on Aclarubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma Aclarubicin, Cyclophosphamide, Vincristine - Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma | Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 36 | 2026-03-30 | 2026-04-17 |
| Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma Aclarubicin, Cyclophosphamide, Vincristine - Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 37 | 2026-03-30 | 2026-04-17 |
| Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia Aclarubicin, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 112 | 2026-03-15 | 2026-03-20 |
| PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL PD-1 Inhibitors - Acute T Lymphoblastic Leukemia (T-ALL) | Phase 3 | Active not recruiting | Fujian Medical University Union Hospital | 40 | 2025-05-01 | 2026-04-21 |
| Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial rhTPO, Decitabine - Acute Myeloid Leukemia | Phase 3 | Unknown | Huihan Wang | 130 | 2022-01-21 | 2022-05-19 |
| Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study rhTPO - Acute Myeloid Leukemia | Not applicable | Unknown | Huihan Wang | 130 | 2022-01-21 | 2022-02-28 |
| A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated SKLB1028, Salvage Chemotherapy - Acute Myeloid Leukemia (AML) | Phase 3 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 315 | 2021-03-24 | 2021-11-02 |
| Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML Cladribine Injection, Aclarubicin, G-CSF - Acute Myeloid Leukemia, Elderly Patients | Phase 2 | Unknown | Sun Yat-sen University | 34 | 2021-03-01 | 2020-12-17 |
| D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients rhTPO - Acute Myeloid Leukemia | Not applicable | Unknown | Huihan Wang | 20 | 2019-11-01 | 2019-11-19 |
| Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF - Acute Myeloid Leukemia, Induction Chemotherapy | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 50 | 2019-04-01 | 2019-09-10 |
| Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients AraC, Aclarubicin, Peg-G-CSF - Acute Myeloid Leukemia | Phase 2 | Unknown | Shandong University | 120 | 2017-01-01 | 2017-02-07 |
| Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy aclarubicin - Vasculopathy, Retinal, With Cerebral Leukodystrophy, Cerebroretinal Vasculopathy, Hereditary | Phase 1 | Completed | Washington University School of Medicine | 4 | 2016-12-05 | 2020-11-19 |
| Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia Cladribine, G-CSF, Aclarubicin - Acute Myeloid Leukemia, Relapse Leukemia | Phase 2 | Unknown | Sun Yat-sen University | 48 | 2016-01-01 | 2019-08-20 |
Leukemia, Myeloid, Acute (9) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Sezary Syndrome (1) · Vasculopathy, Retinal, With Cerebral Leukodystrophy (1)
Huihan Wang (3) · Shanghai Jiao Tong University School of Medicine (3) · Sun Yat-sen University (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Fujian Medical University Union Hospital (1) · Shandong University (1) · The First Affiliated Hospital of Soochow University (1) · Washington University School of Medicine (1)
China (12) · United States (1)
Huihan Wang, Doctor (2) · Junmin Li, Professor (2) · John P Atkinson, MD (1) · Junmin Li (1) · Liang Wang, M.D. (1) · Shaoyuan Wang, Pro (1) · Xiaowen Tang, Ph.D. (1)